Castleman disease

Castleman disease (CD) is a benign lymphoproliferative disorder that may present as a localized or multicentric form (see these terms). The clinical manifestations are heterogeneous, ranging from asymptomatic discrete lymphadenopathy to recurrent episodes of diffuse lymphadenopathy with severe systemic symptoms.

Rheumatoid arthritis

Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures.


Total: 1

                      


(per page)
PMID (PMCID)
24630585
FEMALE Middle Aged
[Paradoxical cutaneous reactions associated with tocilizumab therapy].
Sparsa L, Afif N, Bularca S, Fricker A, Thiebault S, Dahan E, Wendling D, Sibilia J, Ardizzone M.
Rev Med Interne. 2014;35(9):613-6.
Tocilizumab (TCZ) is a humanized antihuman interleukin (IL)-6 receptor antibody recommended for the treatment of moderate to severe active rheumatoid arthritis, adult-onset Still disease, Castleman disease and more recently, systemic juvenile idiopathic arthritis.